Longeveron LGVN

NASDAQ LGVN

$1.43 -0.07 (-4.67%)

At close: Oct 21, 2026 · 4:00 PM EDT

Longeveron (LGVN) stock price is $1.43, down 4.67% on the day, as of Oct 21, 2026. It has a market cap of $4.67Mn, and is classified in the Gene and Cell Therapy industry (Healthcare sector).

Key Stats

Market Cap4.67 Mn

P/E-0.20

P/S3.93

Div. Yield0.00

Revenue Growth (1y) (Qtr)-9.18

Add ratio to table…

About

Longeveron is a clinical stage biotechnology company dedicated to developing regenerative medicines for unmet medical needs, with its lead investigational product candidate laromestrocel (Lomecel-B®) at the forefront of clinical advancement. Laromestrocel represents a proprietary, scalable allogeneic cellular therapy manufactured from culture-expanded human mesenchymal stem cells sourced from donor bone marrow, designed to promote tissue repair by promoting vascular activity, supporting regeneration, and reducing inflammation. The company concentrates its development efforts on four specific indications: hypoplastic left heart syndrome (a critical congenital heart defect affecting approximately 1,000 U. S. newborns annually), Alzheimer's disease (impacting an estimated 6.7 million Americans aged 65 and older), pediatric dilated cardiomyopathy, and aging-related frailty. Longeveron maintains a current good manufacturing practice facility in Miami, Florida that includes approximately 3,000 square feet of cGMP space across eight ISO 7 cleanrooms to support early-phase clinical production while advancing toward potential commercial-scale solutions through third-party partnerships.

Longeveron derives its limited revenue from opportunistic contract manufacturing and development services provided to external biotechnology sponsors utilizing available capacity at its Miami-based cGMP facility. Under a five-year Supply Agreement executed in February 2024 with a third-party company developing novel secretome therapeutics, Longeveron delivers manufacturing execution, quality control testing, release certification, and stability study services for the partner's product candidates. The financial structure of this arrangement includes an initial upfront payment, variable fees per service item executed, monthly charges for manufacturing suite reservation, and hourly rates for project management oversight, although utilization of this agreement diminished considerably throughout 2025 as Longeveron concentrated resources on internal clinical programs for laromestrocel with particular focus on the hypoplastic left heart syndrome indication.

Longeveron participates in the regenerative medicine industry characterized by intense competition among companies developing cell-based therapies, with particular relevance to firms focused on mesenchymal stem cell applications. Direct competitors encompass Mesoblast (achieving FDA approval for remestemcel-L in December 2024 to treat steroid resistant acute graft versus host disease in pediatric patients), BlueRock Therapeutics (advancing dopamine neuron replacement therapy for Parkinson's disease), BioCardia (pursuing autologous cell therapies for ischemic heart failure and chronic myocardial ischemia), and Stemedica Cell Technologies (targeting indications including ischemic stroke, Alzheimer's disease, and heart failure). Longeveron sustains a competitive edge through its vertically integrated operational model featuring early-stage domestic manufacturing capabilities, a robust intellectual property estate comprising numerous patent families covering diverse therapeutic uses of its stem cell technology, and strategic regulatory engagement evidenced by multiple FDA Fast Track designations and a Regenerative Medicine Advanced Therapy award for laromestrocel in Alzheimer's disease granted in July 2024.

Longeveron's revenue-generating customer base comprises third-party biotechnology entities that contract the company's manufacturing expertise for early-stage biologic production and process development. These relationships, illustrated by the confidential counterparty in the secretome supply agreement, involve organizations seeking compliant outsourced solutions for manufacturing, testing, and releasing investigational products under current good manufacturing practice requirements. Simultaneously, Longeveron collaborates with a network of clinical trial sites including hospitals, academic medical centers, and specialized research facilities across the United States to conduct its ongoing studies in hypoplastic left heart syndrome (supported by NIH/NHLBI collaboration, including the ELPIS II trial), Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty, though these investigative partners function strictly as research collaborators without contributing to revenue. As Longeveron remains in the clinical development stage with no products approved for commercial sale, it does not currently maintain any customer relationships involving end-user patients, healthcare providers, or pharmaceutical distributors in a sales or reimbursement context.

Investment Thesis

▲ Bull case

Longeveron is positioned for significant value inflection driven by the imminent August 2026 top-line data readout from the ELPIS II trial for Lomecel-B in HLHS, which management identifies as their most important near-term catalyst. Despite the FDA's initial concern regarding RVEF as a primary endpoint, the company has proactively addressed this by designing ELPIS II to capture robust, objective efficacy measures including all-cause mortality, cardiac transplant-free survival, and well-defined MACE events—criteria explicitly endorsed by the FDA as informative of efficacy in the Type C meeting. Furthermore, insights from the concurrently run Child Study, which showed meaningful differences between treated and standard-of-care patients in the same endpoints, provide strong internal validation that ELPIS II is adequately powered to detect a clinically meaningful treatment effect. This de-risks the regulatory path forward, as the company plans to submit a sponsored Statistical Analysis Plan for FDA review and remains optimistic about supporting a BLA filing post-readout, with potential pre-BLA discussions slated for late 2027. The market may be underestimating the probability of positive results given the mechanistic plausibility of Lomecel-B’s anti-inflammatory, pro-vascular, and pro-regenerative actions in a disease with high unmet need, coupled with the FDA’s clear acknowledgment of HLHS as a rare, life-threatening condition warranting expedited pathways.
Beyond HLHS, Longeveron’s pipeline contains multiple near-term value drivers that are underappreciated by the market, particularly the IND-enabling status of Lomecel-B for pediatric dilated cardiomyopathy (PDCM), which became effective in July 2025 and allows direct entry into a single Phase 2 registrational trial. Management indicated that planning and preparation for the PDCM study are underway in 2026, with potential initiation in 2027, and critically, the clinical endpoint for PDCM was already agreed upon with the FDA—a significant de-risking factor often overlooked in early-stage biotech assessments. Unlike HLHS, where endpoint alignment required post-hoc negotiation, the PDCM program benefits from pre-validated approvability criteria, increasing the likelihood of a smoother regulatory trajectory. Additionally, the company’s broader pipeline in Alzheimer’s disease and aging-related frailty—though less advanced—represents diversified shot-on-goal opportunities, with Joshua Hare emphasizing their role as a “very strong carrier” of the company’s long-term value. The asset-light, partnership-focused strategy announced post-CEO transition—including active outreach at BIO 2026 to secure licensing deals—further enhances capital efficiency and scalability, transforming Longeveron from a pure-play developer into a potential partner of choice for large pharma seeking innovative stem cell therapies in niche indications.
Financially, Longeveron has strengthened its operating runway through disciplined cost control and successful capital raising, with $15.8 million in cash and cash equivalents as of March 31, 2026—sufficient to fund operations into 2026 per CFO Lisa Locklear’s guidance. This liquidity position was bolstered by new investments from premier life sciences funds including Coastland Capital, Janus Henderson Investments, Logos Capital, and Matthew Perry, signaling strong institutional conviction in the company’s repositioned strategy. Notably, while contract manufacturing revenue declined due to reduced third-party demand, clinical trial revenue grew 46% year-over-year driven by increased participant enrollment in the Bahamas registry trial, reflecting underlying demand for Longeveron’s platform capabilities. General and administrative expenses decreased 7% and R&D expenses dropped 8% year-over-year, primarily due to lower performance-based bonuses, indicating effective cost management without compromising core clinical progress. The net loss narrowed by $300 thousand (6%) year-over-year despite increased clinical spend for ELPIS II readiness, demonstrating improved operational efficiency. This financial resilience reduces near-term dilution risk and provides the flexibility to withstand potential delays in HLHS readout while advancing parallel programs like PDCM, a factor the market may be overlooking amid biotech sector-wide cash burn concerns.

Longeveron is positioned for significant value inflection driven by the imminent August 2026 top-line data readout from the ELPIS II trial for Lomecel-B in HLHS, which management identifies as their most important near-term catalyst. Despite the FDA's initial concern regarding RVEF as a primary endpoint, the company has proactively addressed this by designing ELPIS II to capture robust, objective efficacy measures including all-cause mortality, cardiac transplant-free survival, and well-defined MACE events—criteria explicitly endorsed by the FDA as informative of efficacy in the Type C meeting. Furthermore, insights from the concurrently run Child Study, which showed meaningful differences between treated and standard-of-care patients in the same endpoints, provide strong internal validation that ELPIS II is adequately powered to detect a clinically meaningful treatment effect. This de-risks the regulatory path forward, as the company plans to submit a sponsored Statistical Analysis Plan for FDA review and remains optimistic about supporting a BLA filing post-readout, with potential pre-BLA discussions slated for late 2027. The market may be underestimating the probability of positive results given the mechanistic plausibility of Lomecel-B’s anti-inflammatory, pro-vascular, and pro-regenerative actions in a disease with high unmet need, coupled with the FDA’s clear acknowledgment of HLHS as a rare, life-threatening condition warranting expedited pathways.
Beyond HLHS, Longeveron’s pipeline contains multiple near-term value drivers that are underappreciated by the market, particularly the IND-enabling status of Lomecel-B for pediatric dilated cardiomyopathy (PDCM), which became effective in July 2025 and allows direct entry into a single Phase 2 registrational trial. Management indicated that planning and preparation for the PDCM study are underway in 2026, with potential initiation in 2027, and critically, the clinical endpoint for PDCM was already agreed upon with the FDA—a significant de-risking factor often overlooked in early-stage biotech assessments. Unlike HLHS, where endpoint alignment required post-hoc negotiation, the PDCM program benefits from pre-validated approvability criteria, increasing the likelihood of a smoother regulatory trajectory. Additionally, the company’s broader pipeline in Alzheimer’s disease and aging-related frailty—though less advanced—represents diversified shot-on-goal opportunities, with Joshua Hare emphasizing their role as a “very strong carrier” of the company’s long-term value. The asset-light, partnership-focused strategy announced post-CEO transition—including active outreach at BIO 2026 to secure licensing deals—further enhances capital efficiency and scalability, transforming Longeveron from a pure-play developer into a potential partner of choice for large pharma seeking innovative stem cell therapies in niche indications.
Financially, Longeveron has strengthened its operating runway through disciplined cost control and successful capital raising, with $15.8 million in cash and cash equivalents as of March 31, 2026—sufficient to fund operations into 2026 per CFO Lisa Locklear’s guidance. This liquidity position was bolstered by new investments from premier life sciences funds including Coastland Capital, Janus Henderson Investments, Logos Capital, and Matthew Perry, signaling strong institutional conviction in the company’s repositioned strategy. Notably, while contract manufacturing revenue declined due to reduced third-party demand, clinical trial revenue grew 46% year-over-year driven by increased participant enrollment in the Bahamas registry trial, reflecting underlying demand for Longeveron’s platform capabilities. General and administrative expenses decreased 7% and R&D expenses dropped 8% year-over-year, primarily due to lower performance-based bonuses, indicating effective cost management without compromising core clinical progress. The net loss narrowed by $300 thousand (6%) year-over-year despite increased clinical spend for ELPIS II readiness, demonstrating improved operational efficiency. This financial resilience reduces near-term dilution risk and provides the flexibility to withstand potential delays in HLHS readout while advancing parallel programs like PDCM, a factor the market may be overlooking amid biotech sector-wide cash burn concerns.

▼ Bear case

Longeveron faces substantial regulatory risk stemming from the FDA’s explicit rejection of right ventricle ejection fraction (RVEF) as a primary endpoint for the ELPIS II trial in HLHS, a concern that was not merely procedural but fundamental to the trial’s pivotal status designation. Although the company is capturing alternative endpoints such as mortality and transplant-free survival, the FDA’s stance—reinforced in the Type C meeting—indicates deep skepticism about whether the current ELPIS II design can support a definitive efficacy conclusion, especially given the rare disease population and small sample size (n=40). The agency’s condition that only “the most objective measures” could be informative, coupled with the requirement for a sponsored Statistical Analysis Plan (SAP) submission for review, introduces significant uncertainty: even if the data appear favorable, the FDA may ultimately deem the endpoint package insufficient for approval without further trial redesign or additional data. This regulatory hurdle is compounded by the candid admission from management that they were “surprised” by the feedback, suggesting a potential misalignment between internal expectations and regulatory reality, which could delay BLA filing beyond the anticipated late 2026/early 2027 timeline and erode investor confidence.
Beyond HLHS, the pipeline programs—while diverse—are largely preclinical or early-stage, creating a significant execution risk that the market may be underestimating. Although the PDCM IND is effective and allows for a Phase 2 registrational trial, initiation is not expected until 2027, meaning near-term value inflection remains singularly dependent on HLHS outcomes. The Alzheimer’s disease and aging-related frailty programs lack disclosed timelines, IND status, or clinical data, rendering them speculative assets with unclear milestones. Furthermore, the company’s reliance on partnership-driven value creation—emphasized by both Willard and Hare—introduces dependency risk: despite active outreach at BIO 2026, no deals were announced during or immediately following the call, and the absence of upfront payments or milestones from potential partners leaves the asset-light strategy unproven. The historical difficulty of securing partnerships in regenerative medicine, particularly for allogeneic stem cell therapies with complex manufacturing and dosing regimens, suggests that Longeveron may struggle to attract favorable terms without Phase 3 data, potentially forcing it to bear disproportionate development costs.
Financially, Longeveron’s current cash runway, while sufficient into 2026 per CFO guidance, leaves minimal buffer for delays or setbacks, especially given the capital intensity of scaling stem cell therapies. The $15.8 million cash balance as of March 31, 2026, must cover not only ongoing R&D and G&A expenses but also the costs associated with ELPIS II data analysis, SAP preparation, potential Type B/C meetings with the FDA, and preparatory work for PDCM—all while maintaining operations. Although net loss improved slightly year-over-year, this was driven largely by non-recurring factors (lower performance bonuses and prior-year patent amortization), not sustainable operational efficiency. Crucially, R&D expenses decreased only due to reduced bonus accruals, not lower clinical investment, and the company acknowledged increasing clinical spend specifically for ELPIS II readiness—a trend that will reverse post-readout if additional trials or manufacturing scale-up are needed. With no product revenue and continued reliance on dilutive financing to date, any extension of the runway beyond 2026 would likely require further capital raises at potentially unfavorable terms, especially if HLHS data are ambiguous or negative, creating a toxic financing overhang that could suppress valuation regardless of long-term potential.

Longeveron faces substantial regulatory risk stemming from the FDA’s explicit rejection of right ventricle ejection fraction (RVEF) as a primary endpoint for the ELPIS II trial in HLHS, a concern that was not merely procedural but fundamental to the trial’s pivotal status designation. Although the company is capturing alternative endpoints such as mortality and transplant-free survival, the FDA’s stance—reinforced in the Type C meeting—indicates deep skepticism about whether the current ELPIS II design can support a definitive efficacy conclusion, especially given the rare disease population and small sample size (n=40). The agency’s condition that only “the most objective measures” could be informative, coupled with the requirement for a sponsored Statistical Analysis Plan (SAP) submission for review, introduces significant uncertainty: even if the data appear favorable, the FDA may ultimately deem the endpoint package insufficient for approval without further trial redesign or additional data. This regulatory hurdle is compounded by the candid admission from management that they were “surprised” by the feedback, suggesting a potential misalignment between internal expectations and regulatory reality, which could delay BLA filing beyond the anticipated late 2026/early 2027 timeline and erode investor confidence.
Beyond HLHS, the pipeline programs—while diverse—are largely preclinical or early-stage, creating a significant execution risk that the market may be underestimating. Although the PDCM IND is effective and allows for a Phase 2 registrational trial, initiation is not expected until 2027, meaning near-term value inflection remains singularly dependent on HLHS outcomes. The Alzheimer’s disease and aging-related frailty programs lack disclosed timelines, IND status, or clinical data, rendering them speculative assets with unclear milestones. Furthermore, the company’s reliance on partnership-driven value creation—emphasized by both Willard and Hare—introduces dependency risk: despite active outreach at BIO 2026, no deals were announced during or immediately following the call, and the absence of upfront payments or milestones from potential partners leaves the asset-light strategy unproven. The historical difficulty of securing partnerships in regenerative medicine, particularly for allogeneic stem cell therapies with complex manufacturing and dosing regimens, suggests that Longeveron may struggle to attract favorable terms without Phase 3 data, potentially forcing it to bear disproportionate development costs.
Financially, Longeveron’s current cash runway, while sufficient into 2026 per CFO guidance, leaves minimal buffer for delays or setbacks, especially given the capital intensity of scaling stem cell therapies. The $15.8 million cash balance as of March 31, 2026, must cover not only ongoing R&D and G&A expenses but also the costs associated with ELPIS II data analysis, SAP preparation, potential Type B/C meetings with the FDA, and preparatory work for PDCM—all while maintaining operations. Although net loss improved slightly year-over-year, this was driven largely by non-recurring factors (lower performance bonuses and prior-year patent amortization), not sustainable operational efficiency. Crucially, R&D expenses decreased only due to reduced bonus accruals, not lower clinical investment, and the company acknowledged increasing clinical spend specifically for ELPIS II readiness—a trend that will reverse post-readout if additional trials or manufacturing scale-up are needed. With no product revenue and continued reliance on dilutive financing to date, any extension of the runway beyond 2026 would likely require further capital raises at potentially unfavorable terms, especially if HLHS data are ambiguous or negative, creating a toxic financing overhang that could suppress valuation regardless of long-term potential.

Product and Service Breakdown of Revenue (2025)

History

Segments Breakdown of Revenue (2025)

History

Peer percentiles

How Longeveron ranks

Ranked against the 668 companies in Pharmaceuticals and Biotechnology58 metrics · as of Oct 21, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −0.20xMedian 16.8x 8^th
P/FCFNegative free cash flow −0.22xMedian 18.3x 7^th
P/Operating cash flowNegative operating cash flow −0.22xMedian 17.0x 6^th
P/S 3.83xMedian 9.38x 67^th
P/B 0.44xMedian 2.17x 89^th
P/Tangible book 0.55xMedian 2.42x 87^th
EV/EBITDANet cash exceeds market value 0.25xMedian 15.7x Not meaningful —
EV/EBITNet cash exceeds market value 0.24xMedian 19.8x Not meaningful —
EV/RevenueNet cash exceeds market value −4.68xMedian 6.59x Not meaningful —
EV/FCFNet cash exceeds market value 0.27xMedian 19.2x Not meaningful —
EV/Operating cash flowNet cash exceeds market value 0.27xMedian 16.0x Not meaningful —
PEG (3Y EPS CAGR)Negative earnings 0.00Median 0.33 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) −42.7%Median 10.2% 18^th
Revenue CAGR (3Y) 10.4%Median 10.2% 50^th
Gross profit growth (1Y) −49.3%Median 10.6% 13^th
Gross profit CAGR (3Y) 59.0%Median 10.7% 84^th
Operating income growth (1Y) −21.3%Median 0.0% 34^th
Operating income CAGR (3Y) −4.3%Median 1.6% 42^nd
Net income growth (1Y) −26.3%Median −5.1% 38^th
Net income CAGR (3Y) −5.5%Median −0.4% 45^th
EPS growth (1Y) 39.9%Median 21.0% 63^rd
EPS CAGR (3Y) 57.1%Median 25.3% 80^th
Operating cash flow growth (1Y) −40.4%Median 0.3% 23^rd
Operating cash flow CAGR (3Y) −6.2%Median 2.4% 39^th
Free cash flow growth (1Y) −35.6%Median 0.3% 25^th
Free cash flow CAGR (3Y) −5.3%Median 3.3% 39^th

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 69.8%Median 74.0% 42^nd
EBITDA margin −1,907%Median −216% 24^th
Operating margin −1,993%Median −230% 24^th
Pretax margin −1,993%Median −223% 23^rd
Net margin −1,978%Median −230% 24^th
FCF margin −1,730%Median −168% 21^st
Operating cash flow margin −1,716%Median −157% 21^st
Return on equity −179%Median −53.5% 17^th
Return on assets −129%Median −42.0% 16^th
Return on invested capital —Median −5.3% No data —
Return on capital employed −168%Median −46.0% 13^th
Asset turnover 0.06xMedian 0.18x 35^th
Cash conversion (OCF / net income)Net income is not positive 0.87xMedian 1.21x Not meaningful —
Stock comp / revenue 133%Median 27.5% 30^th

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets —Median 20.0% No data —
Debt / equity —Median 0.26x No data —
Net debt / EBITDA —Median 1.82x No data —
Debt / FCF —Median 3.03x No data —
Liabilities / assets 32.8%Median 32.8% 50^th
Equity / assets 67.2%Median 67.2% 50^th
Interest coverage —Median −10.1x No data —
Current ratio 2.63xMedian 4.48x 34^th
Quick ratio 2.36xMedian 3.72x 38^th
Cash ratio 2.35xMedian 3.34x 42^nd
Altman Z-score −16.8Median −0.62 16^th

Shareholder Returns

7 metrics · Cash returned through dividends and buybacks; a lower payout ranks higher

Dividend yield —Median 2.4% No dividend —
Net buyback yieldAbove 100% of market value −140%Median −3.3% Not meaningful —
Shareholder yieldAbove 100% of market value −140%Median −2.3% Not meaningful —
Payout ratio (earnings) —Median 50.9% No dividend —
Payout ratio (FCF) —Median 45.2% No dividend —
Dividend growth (1Y) —Median 3.9% No dividend —
Dividend CAGR (3Y) —Median 3.5% No dividend —

Peer group

Peer Comparison

Companies in the Gene and Cell Therapy

View all peers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,136.97 Bn	42.57	14.27	54.91 Bn
2	JNJ	Johnson & Johnson	619.72 Bn	29.46	6.33	49.04 Bn
3	ABBV	AbbVie Inc.	503.40 Bn	79.78	7.82	70.82 Bn
4	MRK	Merck & Co., Inc.	370.15 Bn	116.66	5.56	53.91 Bn
5	NVS	Novartis Ag	298.64 Bn	18.93	5.45	9.59 Bn
6	AZN	Astrazeneca Plc	261.07 Bn	24.99	4.45	32.35 Bn
7	AMGN	Amgen Inc	237.00 Bn	27.11	6.22	57.30 Bn
8	LGVN	Longeveron Inc.	0.00 Bn	-0.20	3.93	-